Physician profile

Ralph W Raper

Internal Medicine · Allen Park, MI

NPI 1306817523

$3,442.49

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $571.97 2019-2022
Pfizer INC. $325.61 2019-2022
Janssen Pharmaceuticals, INC $312.04 2019-2022
Novartis Pharmaceuticals Corporation $292.82 2019-2022
Astellas Pharma US INC $284.34 2019-2022
Amgen INC. $224.08 2019-2022
E.R. Squibb & Sons, L.L.C. $205.56 2019-2020
Merck Sharp & Dohme LLC $194.06 2019-2021
Allergan, INC. $182.01 2019
Sanofi-Aventis U.S. LLC $140.09 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $134.83 2019
Lilly USA, LLC $125.48 2019-2022
Novo Nordisk INC $73.27 2019-2021
Horizon Therapeutics Plc $54.91 2021-2022
Glaxosmithkline, LLC. $53.39 2019-2022
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Abbvie INC. $38.83 2021
Eisai INC. $38.48 2019
Urovant Sciences INC $34.27 2022
Biogen, INC. $32.80 2021
Acadia Pharmaceuticals INC $19.22 2021
Amarin Pharma, INC. $17.33 2022
Sanofi Pasteur INC. $12.50 2021
Astrazeneca Pharmaceuticals Lp $11.27 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ralph W Raper

$3,442.49

in general payments reported 2019-2025

Years
2019-2022
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/13311/ralph-w-raper

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.